Exercise intolerance in Glycogen Storage Disease Type III: Weakness or energy deficiency?

2013 ◽  
Vol 109 (1) ◽  
pp. 14-20 ◽  
Author(s):  
Nicolai Preisler ◽  
Agnès Pradel ◽  
Edith Husu ◽  
Karen Lindhardt Madsen ◽  
Marie-Hélène Becquemin ◽  
...  
2018 ◽  
Vol 50 (01) ◽  
pp. 022-030 ◽  
Author(s):  
Sana Ben Messaoud ◽  
Rim Ben Abdelaziz ◽  
Nadia Ben Ali ◽  
Hela Boudabous ◽  
Ines Ben Abdelaziz ◽  
...  

Background Our aim was to describe the natural history of neuromuscular involvement (NMI) in glycogen storage disease type III (GSDIII). Methods We conducted a longitudinal study of 50 Tunisian patients, 9.87 years old in average. Results NMI was diagnosed at an average age of 2.66 years and was clinically overt in 85% of patients. Patients with clinical features were older (p = 0.001). Complaints were dominated by exercise intolerance (80%), noticed at 5.33 years in average. Physical signs, observed at 6.75 years in average, were dominated by muscle weakness (62%). Functional impairment was observed in 64% of patients, without any link with age (p = 0.255). Among 33 patients, 7 improved. Creatine kinase (CK) and aspartate aminotransferase (AST) levels were higher with age.Electrophysiological abnormalities, diagnosed in average at 6.5 years, were more frequent after the first decade (p = 0.0005). Myogenic pattern was predominant (42%). Nerve conduction velocities were slow in two patients. Lower caloric intake was associated with more frequent clinical and electrophysiological features. Higher protein intake was related to fewer complaints and physical anomalies. Conclusion Neuromuscular investigation is warranted even in asymptomatic patients, as early as the diagnosis of GSDIII is suspected. Muscle involvement can be disabling even in children. Favorable evolution is possible in case of optimal diet.


2018 ◽  
Vol 6 (4) ◽  
pp. 233-240
Author(s):  
Aditi Korlimarla ◽  
Stephanie Austin ◽  
Baodong Sun ◽  
Priya Kishnani

Author(s):  
María Clemente ◽  
Miquel Gussinyer ◽  
José Antonio Arranz ◽  
Encarnació Riudor ◽  
Diego Yeste ◽  
...  

Author(s):  
Hanaa El-Karaksy ◽  
Mona S. El-Raziky ◽  
Ghada Anwar ◽  
Engy Mogahed

AbstractTo determine the individual fasting tolerance for patients with glycogen storage disease type III (GSD III) and to assess their linear growth velocity after tailoring of dose intervals of oral uncooked cornstarch.A prospective cohort study included 32 patients with GSD III aged 6 months–11.5 years (median: 3.3 years). The fasting tolerance of each patient was determined as the time interval between starch administration until the drop in blood glucose level was below 60 mg/dL.Some 27 patients (84.4%) developed hypoglycemia. The intervals between oral cornstarch administration were tailored for each child according to his/her individual fasting tolerance. After a 6-month follow up there was a significant reduction in seizure attacks (p<0.01) and liver size (p<0.01), but there was no statistically significant difference in liver transaminase and serum lactate levels. There was a significant improvement in height (p<0.01) and linear growth velocity (p<0.05) of these patients after at least a 12-month follow up.: Adjusting the intervals between the cornstarch doses for each patient with GSD III, according to individual fasting tolerance test was very beneficial and resulted in improvement of the linear growth velocity and reduction in the frequency of hypoglycemic seizures as well as the size of the liver. Individual scheduling of cornstarch doses prevents complications in those who develop hypoglycemia at short intervals; it also allows some relaxation in schedule for those who can tolerate longer fasting hours to improve their appetite and prolong their uninterrupted sleep hours.


Sign in / Sign up

Export Citation Format

Share Document